

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alcassedan, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/576,712	05/15/2006	Christian Hesslinger	27319U	6309
34375 NATH & ASS	7590 05/29/200 OCIATES PLLC	EXAMINER		
112 South We	st Street	SZNAIDMAN, MARCOS L		
Alexandria, V.	A 22314		ART UNIT	PAPER NUMBER
			1612	
			MAIL DATE	DELIVERY MODE
			05/29/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/576,712	HESSLINGER ET AL.		
Examiner	Art Unit		
MARCOS SZNAIDMAN	1612		

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED <u>04 May 2009</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
<ol> <li>In ereply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the</li> </ol>
application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request
for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time
periods:
a) X The period for reply expires 4 months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee
have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee
under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as
set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed,
may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a

Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. X The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) ☑ They raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)). The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. X For purposes of appeal, the proposed amendment(s): a) X will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-7 and 11-15. Claim(s) withdrawn from consideration: \_\_\_ AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and

was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be

entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.

12.	Ш	Note the atta	ched Information	n <i>Disclosure</i>	Statement(s).	(PTO/SB/08)	Paper No(s)	_
13.		Other:						

/Frederick Krass/ Supervisory Patent Examiner, Art Unit 1612 /Marcos Sznaidman/

NOTICE OF APPEAL

Continuation of 3. NOTE: The new limitation in claims 1, 4, 6, 11 and 14: "consisting of" changes the scope of the claims and was not presented prior to the Final Office Action, and thus will require further consideration. The proposed amendment will require further consideration and search to determine if these new compositions are novel or nonobvious and if they fairly suggest, teach or disclose the treatment of respiratory diseases like COPD. Additionally, the removal of "to a patient in need thereof" changes the scope of the claims such that they are potentially read upon by any administration of the claimed compounds, necessitating consideration of a potential new rejection under 35 USC 102, and under 35 USC 112, second paragraph as well (since the claim could be considered incomplete insofar as the verb "administering" would have no object upon which to act).

Continuation of 11, does NOT place the application in condition for allowance because: Applicant's arguments that the newly amended claims are patentable over the prior art references are most at this time due to non-entry of the proposed amendment,